Followers | 14 |
Posts | 1,650 |
Boards Moderated | 0 |
Alias Born | 11/01/2010 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
this hit .018 today!? someone got lucky
damn I sold some at .003 did not see this running this far today!
http://www.fiercepharma.com/pharma/federal-hiring-freeze-hurts-generic-competition-industry-warns
In total, there are 4,000 generic applications pending at the FDA, according to GPhA, and 850 open positions at the agency’s Center for Drug Evaluation and Research. Among that group are 150 openings for generic drug reviewers.
I think Trump is about to get the FDA moving
I think this guy would help
http://thehill.com/blogs/pundits-blog/healthcare/315909-2016-fda-drug-approval-numbers-what-can-trump-conclude
possibly the ASK is about to give
someone is buying today
let's go $TXTM
FlutiCare
can we get past .03 without news?
It was exciting to watch this morning and we still finished green
is that new?
lol people buying today
$TXTM nice start to the day
wow big day here
I would be happy to be wrong
I would be happy to be wrong
looks like a big wall at .02 but today has been great so far
$EAPH 0.0394
I think there are traders that are heavily influenced by charts
I just got enriched
$CBIS 0.1295 maybe .13 today?
nice close
Williams %R Check on Shares of Innovus Pharmaceuticals Inc. (INNV)
http://yankeeanalysts.com/2017/01/19/williams-r-check-on-shares-of-innovus-pharmaceuticals-inc-innv/
Dedicated investors tracking Innovus Pharmaceuticals Inc. (INNV) shares may be looking to employ technical stock analysis tools. The Williams Percent Range or Williams %R is a technical indicator that was designed to measure overbought and oversold market conditions. The Williams %R indicator helps show the relative situation of the current price close to the period being observed. Innovus Pharmaceuticals Inc. (INNV)’s Williams Percent Range or 14 day Williams %R presently is at -66.67. In general, if the reading goes above -20, the stock may be considered to be overbought. Alternately, if the indicator goes under -80, this may show the stock as being oversold.
We can also take a look at the Average Directional Index or ADX of the stock. For traders looking to capitalize on trends, the ADX may be an essential technical tool. The ADX is used to measure trend strength. ADX calculations are made based on the moving average price range expansion over a specified amount of time. ADX is charted as a line with values ranging from 0 to 100. The indicator is non-directional meaning that it gauges trend strength whether the stock price is trending higher or lower. The 14-day ADX for Innovus Pharmaceuticals Inc. (INNV) presently sits at 33.39. In general, and ADX value from 0-25 would represent an absent or weak trend. A value of 25-50 would indicate a strong trend. A value of 50-75 would indicate a very strong trend, and a value of 75-100 would signify an extremely strong trend.
At the time of writing, Innovus Pharmaceuticals Inc. (INNV) has a 14-day Commodity Channel Index (CCI) of -52.84. Developed by Donald Lambert, the CCI is a versatile tool that may be used to help spot an emerging trend or provide warning of extreme conditions. CCI generally measures the current price relative to the average price level over a specific time period. CCI is relatively high when prices are much higher than average, and relatively low when prices are much lower than the average.
A commonly used tool among technical stock analysts is the moving average. Moving averages are considered to be lagging indicators that simply take the average price of a stock over a certain period of time. Moving averages can be very helpful for identifying peaks and troughs. They may also be used to assist the trader figure out proper support and resistance levels for the stock. Currently, the 200-day MA is sitting at 0.25.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of stock price movements. The RSI was developed by J. Welles Wilder, and it oscillates between 0 and 100. Generally, the RSI is considered to be oversold when it falls below 30 and overbought when it heads above 70. RSI can be used to detect general trends as well as finding divergences and failure swings. The 14-day RSI is presently standing at 43.49, the 7-day is 43.2, and the 3-day is resting at 27.37.
just need that big revenue report to come out and then we are off
$ZRZH nice .33
I think this was on breakout boards recently or maybe one of other top boards
Seems a bit quiet
looking good
I haven't looked at the board since this afternoon and there are 1100+ unread posts! Did something happen?
maybe MM manipulation
I think the Christie excitement is gone and now we need to see some numbers. Just need some patience.
Not sure I get what's going on but looks good. Maybe the market likes Berholtz?
It's good to see it holding up. Maybe we interpreted the 8K wrong
I sent an email to my local store in Maryland. I hear they have ordered it in the past but I can't confirm yet
Randy Berholtz seems talented
Innovus Pharma Expands its Executive Management Team with the Addition of Randy Berholtz as its Executive Vice President, Corporate Development and General Counsel
http://www.businesswire.com/news/home/20170106005696/en/Innovus-Pharma-Expands-Executive-Management-Team-Addition
Pharma Corporate and Legal veteran Berholtz comes on board as Innovus expands its corporate development and commercialization efforts
January 06, 2017 04:05 PM Eastern Standard Time
SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that Randy Berholtz will join the management team as Executive Vice President, Corporate Development and General Counsel effective January 9, 2017. A life sciences business and legal veteran with decades of experience, Berholtz joins Innovus Pharma to expand its corporate development efforts to find and enter into additional collaborations to expand the breadth and depth of product offerings on a worldwide basis.
“I am very excited to bring on Randy at this important period of commercial growth for Innovus Pharma,” said Dr. Bassam Damaj, Innovus’ Chief Executive Officer. “His business, legal and deal-making expertise and experience will help us to increase our capacity to find, negotiate with and enter into additional acquisitions and partnerships that will help us increase our product offerings and expand our international commercialization efforts to take our company to the next stage.”
“I am very excited to be joining the Innovus Pharma executive team at this important point in the Company’s growth,” said Berholtz. “I look forward to working with Bassam, Robert Hoffman and the entire Innovus Pharma team on growing the Company’s product portfolio, expanding its corporate partnerships and increasing its revenues.”
Berholtz will oversee Innovus Pharma’s corporate development, business development and legal areas.
Mr. Berholtz was recently the founding partner of the Sorrento Valley Law Group, a healthcare and life sciences law firm and had previously been a part-time consultant for the Company from July 2013 to mid-May 2016. Previously, from 2011 to 2013, he was the Executive Vice President, General Counsel and Secretary of Apricus Biosciences, Inc., a biotechnology company (Nasdaq:APRI); from 2004 to 2010, he was the Vice President, General Counsel and Secretary of the ACON Group of private U.S. and Chinese life science companies; from 2003 to 2004, he was the Chief Operating Officer and General Counsel to Inglewood Ventures, a life sciences venture capital firm; and from 2000 to 2003, he held multiple titles and rose to become the Acting General Counsel and Secretary of Nanogen, Inc., a genomics tools company (Nasdaq:NGEN). From 1992 to 2000, Mr. Berholtz was in private practice with law firms in New York and San Diego and from 1990 to 1991, he was a law clerk to Judge Jerry E. Smith on the U.S. Court of Appeals for the Fifth Circuit.
Mr. Berholtz is a member of the board of directors of Hispanica International Delights of America, Inc., an ethnic food company (OTC:HISP) and Larada Health, Inc., a private company in the medical supply business and is a Senior Advisor to Mesa Verde Ventures, a life sciences venture capital firm. Mr. Berholtz received his B.A. from Cornell University, his M.Litt. from Oxford University where he was a Rhodes Scholar, his J.D. from Yale University and his M.B.A. from the University of San Diego.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for men's and women's health and respiratory diseases. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® to help with reduced penile sensitivity, (f) Zestra Glide®, (g) Vesele® for promoting sexual health, (h) RecalMax™ for promoting brain and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for allergic rhinitis, if its ANDA is approved by the U.S. FDA.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.urivarx.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, additional acquisitions, commercial partnerships, and to achieve its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
Contacts
Chesapeake Group
Kevin Holmes
410-825-3930
info@chesapeakegp.com